Robust Protein Quantification by ELISA
Robust Protein Quantification by ELISA
While new platforms emerge, custom-developed ELISAs remain the gold standard for delivering the precise, highly sensitive protein data required to advance therapeutic candidates through IND-enabling studies. At ImmunitasBio, our bespoke ELISA development services support critical decision-making across your early discovery and preclinical pipelines:
Pharmacokinetics (PK):
Accurately measure the concentration, half-life, and exposure profiles of biologics, recombinant proteins, and advanced delivery vectors in complex in vivo matrices.
Pharmacodynamics (PD) & Target Engagement:
Validate your mechanism of action (MoA) by rigorously quantifying receptor occupancy and downstream protein modulation.
Immunogenicity Assessment (ADA):
De-risk your pipeline early with highly sensitive bridging and competitive assays designed to detect anti-drug and neutralizing antibodies.
Safety & Toxicology Biomarkers:
Monitor acute immune reactions, such as cytokine release profiles, and track organ-specific toxicity markers to establish clear preclinical safety margins.
Preclinical CMC & Potency:
Ensure batch-to-batch consistency, stability, and functional binding with custom lot-release assays tailored to your manufacturing process.
